Sponsors of testosterone products may have more difficulty promoting their products as FDA’s new proposed labeling removes many of the signs and symptoms of low testosterone that sponsors have used to describe the condition and benefits of treatment to the general public.
Disease-awareness ads may take a particular hit as the labels seem to reign in what constitutes a low-testosterone diagnosis.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?